ロード中...
Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department()
AIMS: Ibutilide is a rapid-acting antiarrhythmic drug with worldwide use for conversion of recent-onset atrial fibrillation. Vernakalant, approved in the EU in 2010, is likewise used intravenously, with proven efficacy and safety compared with placebo and amiodarone in randomized clinical trials. Th...
保存先:
| 出版年: | Europace |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5400093/ https://ncbi.nlm.nih.gov/pubmed/28175295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/europace/euw052 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|